Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians

Multikinase inhibitors (MKI) are targeted molecular agents that have revolutionized cancer management. However, there is a paucity of data concerning MKI-related liver injury risk and clinical guidelines for the management toxicity in patients receiving MKI scarce. We conducted PubMed search articles English published from January 2000 to December 2018 related hepatotoxicity 29 FDA-approved MKIs at doses used practice. The terms were international non-proprietary name each agent cross-referenced with «hepatotoxicity», «hepatitis», «hepatic adverse event», or «liver failure», «phase II trial», III «case report». Following this search, 140 relevant studies 99 case reports considered. Although asymptomatic elevation aminotransferase levels has been frequently observed trials, clinically significant rare event. In most cases, interval between treatment initiation onset one week two months. Liver often hepatocellular less mixed. Life-threatening MKI-induced hepatic described, involving fulminant failure death. Starting existing data, description events, grading risk, recommendations also given various molecules. All can potentially cause injury, which sometimes irreversible. As still no strategy available prevent hepatotoxicity, early detection remains crucial. surveillance function during may help hepatotoxicity. Furthermore, exclusion potential causes essential avoid unnecessary withdrawal.